WO2002024158A3 - Pulmonary delivery in treating disorders of the central nervous system - Google Patents

Pulmonary delivery in treating disorders of the central nervous system Download PDF

Info

Publication number
WO2002024158A3
WO2002024158A3 PCT/US2001/029311 US0129311W WO0224158A3 WO 2002024158 A3 WO2002024158 A3 WO 2002024158A3 US 0129311 W US0129311 W US 0129311W WO 0224158 A3 WO0224158 A3 WO 0224158A3
Authority
WO
WIPO (PCT)
Prior art keywords
central nervous
nervous system
drug
particles
pulmonary delivery
Prior art date
Application number
PCT/US2001/029311
Other languages
French (fr)
Other versions
WO2002024158A2 (en
WO2002024158A8 (en
Inventor
Raymond T Bartus
Dwaine E Emerich
Original Assignee
Advanced Inhalation Res Inc
Raymond T Bartus
Dwaine E Emerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/665,252 external-priority patent/US6514482B1/en
Priority to ES01971210.8T priority Critical patent/ES2621549T3/en
Priority to CA2421974A priority patent/CA2421974C/en
Priority to AU2001291122A priority patent/AU2001291122B2/en
Priority to JP2002528195A priority patent/JP5421510B2/en
Priority to DK01971210.8T priority patent/DK1318785T3/en
Application filed by Advanced Inhalation Res Inc, Raymond T Bartus, Dwaine E Emerich filed Critical Advanced Inhalation Res Inc
Priority to EP01971210.8A priority patent/EP1318785B1/en
Priority to AU9112201A priority patent/AU9112201A/en
Publication of WO2002024158A2 publication Critical patent/WO2002024158A2/en
Publication of WO2002024158A3 publication Critical patent/WO2002024158A3/en
Publication of WO2002024158A8 publication Critical patent/WO2002024158A8/en
Priority to CY20171100358T priority patent/CY1118851T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm3. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration.
PCT/US2001/029311 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system WO2002024158A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU9112201A AU9112201A (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system
CA2421974A CA2421974C (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system
AU2001291122A AU2001291122B2 (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system
JP2002528195A JP5421510B2 (en) 2000-09-19 2001-09-19 Pulmonary delivery in the treatment of disorders of the central nervous system
DK01971210.8T DK1318785T3 (en) 2000-09-19 2001-09-19 PULMONAL ADMINISTRATION OF L-DOPA
ES01971210.8T ES2621549T3 (en) 2000-09-19 2001-09-19 L-Dopa pulmonary administration
EP01971210.8A EP1318785B1 (en) 2000-09-19 2001-09-19 Pulmonary delivery of l-dopa
CY20171100358T CY1118851T1 (en) 2000-09-19 2017-03-21 Pulmonary administration of L-DOPA

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/665,252 US6514482B1 (en) 2000-09-19 2000-09-19 Pulmonary delivery in treating disorders of the central nervous system
US09/665,252 2000-09-19
US09/877,734 US6613308B2 (en) 2000-09-19 2001-06-08 Pulmonary delivery in treating disorders of the central nervous system
US09/877,734 2001-06-08

Publications (3)

Publication Number Publication Date
WO2002024158A2 WO2002024158A2 (en) 2002-03-28
WO2002024158A3 true WO2002024158A3 (en) 2002-09-19
WO2002024158A8 WO2002024158A8 (en) 2003-02-20

Family

ID=27099159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029311 WO2002024158A2 (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system

Country Status (10)

Country Link
US (7) US6613308B2 (en)
EP (2) EP3061453A1 (en)
JP (2) JP5421510B2 (en)
AU (2) AU9112201A (en)
CA (1) CA2421974C (en)
CY (1) CY1118851T1 (en)
DK (1) DK1318785T3 (en)
ES (1) ES2621549T3 (en)
PT (1) PT1318785T (en)
WO (1) WO2002024158A2 (en)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US7779020B2 (en) * 2002-03-01 2010-08-17 International Business Machines Corporation Small-footprint applicative query interpreter method, system and program product
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
FR2812545B1 (en) * 2000-08-03 2003-03-28 Air Liquide Sante Int INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002094232A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of antidepressants through an inhalation route
US20030032638A1 (en) * 2001-05-24 2003-02-13 Kim John J. Delivery of benzodiazepines through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
WO2002094230A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of sedative-hypnotics trough an inhalation route
DE60230502D1 (en) * 2001-05-24 2009-02-05 Alexza Pharmaceuticals Inc ADMINISTRATION OF ANTIMIZING DRUGS BY INHALATION
DE60231611D1 (en) * 2001-05-24 2009-04-30 Alexza Pharmaceuticals Inc ADMINISTRATION OF OPIOIDES BY INHALATION
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7078016B2 (en) 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
WO2002094237A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of beta-blockers through an inhalation route
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
WO2002094242A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
JP4357842B2 (en) * 2001-05-24 2009-11-04 アレックザ ファーマシューティカルズ, インコーポレイテッド Delivery of alprazolam, estazolam, midazolam or triazolam by a prescribed inhalation route
DE60230609D1 (en) * 2001-05-24 2009-02-12 Alexza Pharmaceuticals Inc ADMINISTRATION OF NON-TEROIDAL INFLAMMATION OF INHALATION OF ACTIVE SUBSTANCES
DE60227660D1 (en) * 2001-05-24 2008-08-28 Alexza Pharmaceuticals Inc RELEASE OF ANTIEMETICS ON THE INHALATION PATH
DE10137633A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Treatment or prophylaxis of attention deficit hyperactivity disorder, using the dopamine agonist pramexipol or its salt
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
PT1531798E (en) * 2002-03-20 2012-09-10 Civitas Therapeutics Inc Pulmonary delivery for levodopa
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
JP2005521695A (en) * 2002-03-20 2005-07-21 アドバンスト インハレーション リサーチ,インコーポレイテッド Method of administering growth hormone by pulmonary delivery
JP2005529123A (en) * 2002-04-24 2005-09-29 リサーチ ディベロップメント ファンデーション Synergistic effect of nuclear transcriptional regulator NF-κB inhibitor and antitumor agent
US8003080B2 (en) 2002-05-13 2011-08-23 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
EP1523318A4 (en) * 2002-06-24 2007-07-04 Res Dev Foundation Treatment of human multiple myeloma by curcumin
ES2638987T3 (en) * 2002-06-28 2017-10-25 Civitas Therapeutics, Inc. Inhalable epinephrine
US20060094785A1 (en) * 2002-07-12 2006-05-04 Guttuso Jr Thomas J Use of amino acids for treatment of various conditions
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
WO2004047844A1 (en) * 2002-11-26 2004-06-10 Alexza Pharmaceuticals, Inc. Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
MXPA05005609A (en) * 2002-11-26 2005-07-26 Alexza Pharmaceuticals Inc Treatment of headache with antipsychotics delivered by inhalation.
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
AU2003297087B2 (en) * 2003-02-04 2009-06-11 Philip Morris Products S.A. Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
AU2004231342A1 (en) 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
ES2370395T3 (en) 2003-05-21 2011-12-15 Alexza Pharmaceuticals, Inc. USE OF A SOLID FUEL LAYER, MANUFACTURING PROCEDURE AND CORRESPONDING HEATING UNIT.
US7954491B2 (en) * 2003-06-13 2011-06-07 Civitas Therapeutics, Inc. Low dose pharmaceutical powders for inhalations
US7462646B2 (en) 2003-08-26 2008-12-09 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
WO2005020958A2 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
SI1765288T1 (en) 2004-06-18 2013-02-28 Novartis Ag Tobramycin formualtions for treatment of endobronchial infections
US7709639B2 (en) 2004-08-20 2010-05-04 Mannkind Corporation Catalysis of diketopiperazine synthesis
EP1791542B1 (en) 2004-08-23 2015-05-20 Mannkind Corporation Diketopiperazine salts for drug delivery
ATE487484T1 (en) 2004-09-18 2010-11-15 Univ Maryland THERAPEUTIC AGENTS FOR TARGETING THE NC CA ATP CHANNEL AND METHOD OF USE THEREOF
AU2005290238A1 (en) 2004-09-18 2006-04-06 Department Of Veterans Affairs Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060134009A1 (en) * 2004-12-16 2006-06-22 Daniel Deaver Low dose corticosteroid powders for inhalation
EP3339348B1 (en) 2005-04-22 2019-12-04 Université de Genève Polylactide compositions and uses thereof
ES2559677T3 (en) 2005-09-14 2016-02-15 Mannkind Corporation Drug formulation method based on increasing the affinity of the active ingredients for microcrystalline particle surfaces
KR20080096809A (en) 2006-02-22 2008-11-03 맨카인드 코포레이션 A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
WO2008097835A2 (en) 2007-02-02 2008-08-14 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US20100092469A1 (en) 2007-02-09 2010-04-15 Simard J Marc Antagonists of a non-selective cation channel in neural cells
ES2538082T3 (en) 2007-02-11 2015-06-17 Map Pharmaceuticals Inc Therapeutic administration method of DHE to allow rapid migraine relief while minimizing the side effects profile
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
JP2010533181A (en) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド Methods and compositions for pulmonary administration of TNFα inhibitors
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CA3086027C (en) 2008-06-13 2022-05-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2300083T3 (en) 2008-06-20 2013-07-22 Mannkind Corp INTERACTIVE DEVICE AND PROCEDURE FOR REAL-TIME PROFILING INHALATION TESTS
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Use of ultrarapid acting insulin
KR101704832B1 (en) * 2008-08-15 2017-02-08 아이언우드 파마슈티컬스, 인코포레이티드 Linaclotide-containing formulations for oral administration
EP2340254B8 (en) * 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
EP2326318A4 (en) 2008-09-16 2012-05-23 Univ Maryland Sur1 inhibitors for therapy
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP5671001B2 (en) 2009-03-26 2015-02-18 パルマトリックス,インコーポレイテッド Dry powder formulation and method for treating lung disease
EP3141561B1 (en) 2009-04-24 2018-09-12 Vanderbilt University Anti-tgf-beta induction of bone growth
BRPI1013154B1 (en) 2009-06-12 2020-04-07 Mannkind Corp MICROPARTICLES OF DICETOPIPERAZINE WITH SPECIFIC SURFACE AREAS DEFINED, DRY POWDER UNDERSTANDING THE REFERRED MICROPARTICLES, METHOD FOR FORMATION OF THE REFERENCESMICROPARTICLES AND THE FORMATION OF MICROPARTYSTEMS
US9078865B2 (en) 2009-07-24 2015-07-14 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
MX2012001660A (en) * 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration.
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
PL2536742T3 (en) 2010-02-17 2017-11-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
RU2531455C2 (en) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Systems and methods for dry powder drugs delivery
ES2919136T3 (en) 2010-08-11 2022-07-22 Ironwood Pharmaceuticals Inc Stable formulations of linaclotide
EP3192880B1 (en) 2010-08-18 2019-10-09 Fred Hutchinson Cancer Research Center Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd)
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
RU2017144619A (en) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. CASES OF SINGLE-VALVE METALS OF DRY POWDERS FOR INHALATIONS
MX353285B (en) 2011-04-01 2018-01-05 Mannkind Corp Blister package for pharmaceutical cartridges.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
DK2734634T3 (en) 2011-07-22 2019-10-21 Univ Chicago IGF-1 FOR USE FOR THE TREATMENT OF Migraine
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
US9655905B2 (en) 2011-09-14 2017-05-23 King Abdullah University Of Science And Technology Treatment of sickle cell disease
WO2013041969A2 (en) 2011-09-21 2013-03-28 King Abdullah University Of Science And Technology Didemnin biosynthetic gene cluster in tistrella mobilis
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
KR20140095483A (en) 2011-10-24 2014-08-01 맨카인드 코포레이션 Methods and compositions for treating pain
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20150024037A1 (en) 2012-02-16 2015-01-22 The University Of Toledo Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
AU2013225982B2 (en) 2012-02-29 2017-11-30 Pulmatrix, Inc. Inhalable dry powders
AR092821A1 (en) 2012-04-20 2015-05-06 Sucampo Ag CONJUGATE OF GRASO-POLYMER ACID DERIVATIVE
US10307490B2 (en) 2012-05-23 2019-06-04 The Ohio State University Lipid nanoparticle compositions for antisense oligonucleotides delivery
RU2650035C2 (en) 2012-07-12 2018-04-06 Маннкайнд Корпорейшн Dry powder drug delivery systems and methods
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
JP2015534988A (en) * 2012-10-22 2015-12-07 サイヴィタス セラピューティックス,インコーポレイテッド Reduce patient-to-patient variability of levodopa plasma concentrations
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
BR112015010601B1 (en) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION
EP4335505A2 (en) 2012-11-30 2024-03-13 The Regents of The University of California Anticonvulsant activity of steroids
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
FR3000392B1 (en) * 2012-12-27 2015-03-27 Virbac NOVEL VETERINARY PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THEIR PREPARATION
WO2014160339A1 (en) 2013-03-13 2014-10-02 Board Of Regents, The University Of Texas System Compounds for treating inflammatory and hyperproliferative diseases
CN105102436B (en) 2013-03-15 2018-06-12 曼金德公司 Crystallite diketopiperazine composition and method
EP2978482B1 (en) * 2013-03-26 2022-05-18 Optinose AS Nasal administration
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
EP2981247B1 (en) 2013-04-01 2023-06-07 Pulmatrix Operating Company, Inc. Tiotropium dry powders
EP2991634A1 (en) 2013-04-30 2016-03-09 Otitopic Inc. Dry powder formulations and methods of use
KR102321339B1 (en) 2013-07-18 2021-11-02 맨카인드 코포레이션 Heat-stable dry powder pharmaceutical compositions and methods
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
NZ759287A (en) 2013-12-02 2022-10-28 Baylor College Medicine Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
CN112656780A (en) * 2014-02-20 2021-04-16 奥迪托皮克股份有限公司 Dry powder formulations for inhalation
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US9693994B2 (en) 2014-04-09 2017-07-04 Research Development Foundation Class IIa HDAC inhibitors for the treatment of infection
JP2017513866A (en) * 2014-04-21 2017-06-01 サイヴィタス セラピューティックス,インコーポレイテッド Rapid relief of motor symptom fluctuations in Parkinson's disease
WO2016025202A1 (en) 2014-08-14 2016-02-18 The Regents Of The University Of Colorado Antibody-sirna conjugates and uses therefor
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
ES2841933T3 (en) 2014-10-31 2021-07-12 Univ Monash Powder formulation
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
US11285190B2 (en) 2015-04-20 2022-03-29 The Board Of Regents Of The University Of Texas System CLEC11a is a bone growth agent
EP3288591A1 (en) * 2015-05-01 2018-03-07 Civitas Therapeutics, Inc. Zolmitriptan powders for pulmonary delivery
US10962551B2 (en) 2015-06-17 2021-03-30 The Johns Hopkins University TDP-43 in degenerative disease
KR20180052566A (en) 2015-07-02 2018-05-18 키비타스 테라퓨틱스, 인코포레이티드. Tripentad powder for pulmonary delivery
US10695322B2 (en) 2016-01-29 2020-06-30 The Johns Hopkins University Inhibitors of bacterial growth
US11040025B2 (en) 2016-02-17 2021-06-22 The Johns Hopkins University Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
WO2017147370A1 (en) 2016-02-24 2017-08-31 The Johns Hopkins University Novel antiviral proteins and their uses in therapeutic methods
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
RU2022102537A (en) 2016-03-08 2022-03-30 Сейдж Терапьютикс, Инк. NEUROACTIVE STEROIDS, THEIR COMPOSITIONS AND APPLICATIONS
KR102430891B1 (en) 2016-03-10 2022-08-09 더 존스 홉킨스 유니버시티 Method for preparing aggregate-free monomeric diphtheria toxin fusion protein and therapeutic use
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
EP3429569A4 (en) 2016-03-17 2020-02-26 The Johns Hopkins University Methods for preventing or treating parkinson's disease by the farnesylation of paris
EP3436609B1 (en) 2016-03-30 2022-05-04 The Johns Hopkins University Olfr90 specificity and methods of detection
US11016085B2 (en) 2016-04-25 2021-05-25 The Johns Hopkins University ZNT8 assays for drug development and pharmaceutical compositions
WO2017210658A1 (en) * 2016-06-03 2017-12-07 Otitopic Inc. Dry powder formulations for inhalation
US11149275B2 (en) 2016-10-10 2021-10-19 The Johns Hopkins University Device and method to treat esophageal disorders
DK3551189T3 (en) * 2016-12-09 2024-01-29 Alexza Pharmaceuticals Inc ALPRAZOLAM FOR USE IN THE TREATMENT OF EPILEPSY
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
CN111316099A (en) 2017-07-12 2020-06-19 约翰霍普金斯大学 Proteoliposome-based ZNT8 autoantigen for diagnosis of type 1 diabetes
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
US20200330541A1 (en) 2017-11-16 2020-10-22 University Of Maine System Board Of Trustees Compositions and methods for modulating endothelial cell migration and angiogenesis
US11246857B2 (en) 2017-12-14 2022-02-15 The Johns Hopkins University Anti-fungal inhibitors
EP3921029A4 (en) 2019-02-07 2022-12-07 Baylor College of Medicine Periosteal skeletal stem cells in bone repair
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO2000072827A2 (en) * 1999-05-27 2000-12-07 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2001095874A2 (en) * 2000-06-09 2001-12-20 Advanced Inhalation Research, Inc. Highly efficient delivery of a large therapeutic mass aerosol

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
JPS6122019A (en) 1984-07-06 1986-01-30 Tomio Konno Inhalation cell active chemical and method for using same
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
WO1986006959A1 (en) 1985-05-22 1986-12-04 Liposome Technology, Inc. Liposome inhalation method and system
US4863720A (en) * 1986-03-10 1989-09-05 Walter Burghart Pharmaceutical preparation and methods for its production
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
AU7908791A (en) 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5166202A (en) 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
GB9101592D0 (en) 1991-01-24 1991-03-06 Glaxo Group Ltd Compositions
ATE179605T1 (en) * 1991-02-09 1999-05-15 B S D Bio Science Dev Snc Di O ANTIREACTIVE ANTIASTHMATIC EFFECT OF ACETYL SALICYLIC ACID BY INHALATION
DE69232003T2 (en) 1991-09-18 2002-04-25 Glaxo Group Ltd Benzanilide derivatives as 5-HT1D antagonists
US5457100A (en) 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
US5284133A (en) 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
PL179443B1 (en) 1994-03-07 2000-09-29 Inhale Therapeutic Syst Methods of and compositions for administering insulin into lungs
ATE299892T1 (en) * 1994-05-18 2005-08-15 Nektar Therapeutics METHODS AND COMPOSITIONS FOR DRY POWDER MEDICATION FROM INTERFERONS
CA2152684A1 (en) 1994-07-01 1996-01-02 Richard Anthony Henry Aerosol delivery of midazolam
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6103270A (en) 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
US5958902A (en) 1997-04-16 1999-09-28 Wisconsin Alumni Research Foundation Method and composition for treating sleep apnea
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002094243A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO2000072827A2 (en) * 1999-05-27 2000-12-07 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2001095874A2 (en) * 2000-06-09 2001-12-20 Advanced Inhalation Research, Inc. Highly efficient delivery of a large therapeutic mass aerosol

Also Published As

Publication number Publication date
WO2002024158A2 (en) 2002-03-28
JP2004509141A (en) 2004-03-25
US6979437B2 (en) 2005-12-27
US20090162441A1 (en) 2009-06-25
AU9112201A (en) 2002-04-02
EP1318785B1 (en) 2016-12-21
DK1318785T3 (en) 2017-04-03
PT1318785T (en) 2017-04-19
US20040228923A1 (en) 2004-11-18
CY1118851T1 (en) 2018-01-10
EP1318785A2 (en) 2003-06-18
JP2012180378A (en) 2012-09-20
US20120087952A1 (en) 2012-04-12
US6613308B2 (en) 2003-09-02
AU2001291122B2 (en) 2005-03-10
US20040265242A1 (en) 2004-12-30
CA2421974C (en) 2011-03-29
US20140193501A1 (en) 2014-07-10
JP5421510B2 (en) 2014-02-19
CA2421974A1 (en) 2002-03-28
US20030235537A1 (en) 2003-12-25
US20020058009A1 (en) 2002-05-16
EP3061453A1 (en) 2016-08-31
ES2621549T3 (en) 2017-07-04
WO2002024158A8 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
WO2002024158A8 (en) Pulmonary delivery in treating disorders of the central nervous system
HUP0102892A2 (en) Drug delivery system comprising a tightly compacted solid medicament stock, process for its preparation and for its use
JP2020023542A (en) Mast cell stabilizers for lung disease treatment
WO2003080022A3 (en) Analgesics for nasal administration
WO2017011729A1 (en) Combination therapies for the treatment of lung diseases
AU3400501A (en) Improvements in or relating to the delivery of oral drugs
EA003405B1 (en) Method and device for delivering an aerosolized active agent to the lungs of a human patient
CA2304975A1 (en) Stabilized preparations for use in metered dose inhalers
WO2001074247A3 (en) Method for measuring changes in the airways of humans and other mammals
KR930701992A (en) How to get rid of mucus secretions that remain in the lungs of patients
US7431916B2 (en) Administration of medicinal dry powders
US5679714A (en) Administration of ketamine for detoxification and treatment of tobacco addiction
JP2005521695A (en) Method of administering growth hormone by pulmonary delivery
CA2152684A1 (en) Aerosol delivery of midazolam
EP0814790B1 (en) Administration of ketamine for detoxification
Van Renterghem et al. Intravenous versus nebulized terbutaline in patients with acute severe asthma; a double-blind randomized study
CZ287114B6 (en) Therapeutic preparation in the form of aerosol and use of gas mixture
Crompton Nebulized or intravenous beta 2 adrenoceptor agonist therapy in acute asthma?
CA2265198A1 (en) Method of producing a nicotine medicament and a medicament made by the method
Verbeek et al. Treatment of asthma-related respiratory arrest with endotracheal abuterol (Salbutamol)
Hasani et al. Paediatric premedication: A comparison of sublingual buprenorphine and midazolam in children (4-10 years) scheduled for adenotonsillectomy
US20050154060A1 (en) Anti-inflamatory inhalation pharmaceutical composition
Lahdensuo Bronchodilator effects of fenoterol and salbutamol administered by intermittent positive pressure breathing to patients with asthma or chronic obstructive bronchitis
CN113925849A (en) Dry powder inhalation preparation of expectorant and preparation method thereof
Pauwels Inhalation device, pulmonary deposition and clinical effects of inhaled therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 2001291122

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2421974

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002528195

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2001971210

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001971210

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001971210

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001291122

Country of ref document: AU